Vanda Pharmaceuticals Inc (VNDA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $230.39M
Last updated: Nov 17, 2026 at 4:33 PM ET
Vanda Pharmaceuticals Inc (VNDA) Stock Chart
Vanda Pharmaceuticals (VNDA) has a latest price of $3.81 on Nov 17, 2026, 61.7% below its 52-week high of $9.94. Its price fell 12.4% over the past 12 months. The month-end price fell 74.5% over the 10 years through Oct 2026, a compound annual decline of 12.8%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $27.13 in Jan 2019 and its lowest $3.60 in Jan 2024, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart VNDA with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for VNDA.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 31.6%, and over 6 months it fell 36.4%. The month-end price fell 13.5% over the 3 years through Oct 2026, a compound annual decline of 4.7%.
| Period | Change |
|---|---|
| 1 month | -6.8% |
| 3 months | -31.6% |
| 6 months | -36.4% |
| 12 months | -12.4% |
| 12 months, with dividends | -12.4% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -13.5% | -4.7% |
| 5 years | -77.9% | -26.0% |
| 10 years | -74.5% | -12.8% |
Price by Year
Its best calendar year was 2025, when the price rose 84.1%, and its weakest was 2022, when it fell 52.9%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $3.79 | -57.0% |
| 2025 | $8.82 | +84.1% |
| 2024 | $4.79 | +13.5% |
| 2023 | $4.22 | -42.9% |
| 2022 | $7.39 | -52.9% |
| 2021 | $15.69 | +19.4% |
| 2020 | $13.14 | -19.9% |
| 2019 | $16.41 | -37.2% |
| 2018 | $26.13 | +71.9% |
| 2017 | $15.20 | -4.7% |
Trading Range
The price is 14.1% below its 50-day average of $4.43 and 36.3% below its 200-day average of $5.98.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $3.81 | |
| 52-week high | $9.94 | -61.7% |
| 52-week low | $3.57 | +6.7% |
| 50-day average | $4.43 | -14.1% |
| 200-day average | $5.98 | -36.3% |
Price Risk
Over 3 years, its largest fall from a peak was 62.5%.
| Measure | Value |
|---|---|
| 1-year beta | 1.05 |
| Largest fall, 1 year | -62.4% |
| Largest fall, 3 years | -62.5% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About VNDA
What is VNDA's 1-year price change?
Vanda Pharmaceuticals's price fell 12.4% over the past 12 months. With dividends included, the 12-month total return was -12.4%.
What is VNDA's 5-year price change?
Vanda Pharmaceuticals's month-end price fell 77.9% over the 5 years through Oct 2026, a compound annual decline of 26.0%. These figures leave out dividends.
What is VNDA's 52-week high and low?
Vanda Pharmaceuticals's 52-week high is $9.94 and its 52-week low is $3.57. Its latest price of $3.81 on Nov 17, 2026 is 61.7% below the high.
What is VNDA's beta?
Vanda Pharmaceuticals's 1-year beta against the S&P 500 is 1.05, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 62.4%.
Is the VNDA chart free?
Yes. Advanced Charting for VNDA is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
VNDA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts